These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1135 related articles for article (PubMed ID: 31526368)

  • 21. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR mutations induce the suppression of CD8
    Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S
    J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
    Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer.
    Luo Y; Ma S; Sun Y; Peng S; Zeng Z; Han L; Li S; Sun W; Xu J; Tian X; Wang F; Wu Q; Xiao Y; Zhang J; Gong Y; Xie C
    Int J Biol Sci; 2021; 17(7):1671-1681. PubMed ID: 33994852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.
    Li X; Lian Z; Wang S; Xing L; Yu J
    Cancer Lett; 2018 Apr; 418():1-9. PubMed ID: 29309815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.
    Ma L; Diao B; Huang Z; Wang B; Yu J; Meng X
    Cancer Commun (Lond); 2021 Dec; 41(12):1314-1330. PubMed ID: 34699691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
    Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
    PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.
    Jia Y; Li X; Jiang T; Zhao S; Zhao C; Zhang L; Liu X; Shi J; Qiao M; Luo J; Liu S; Han R; Su C; Ren S; Zhou C
    Int J Cancer; 2019 Sep; 145(5):1432-1444. PubMed ID: 30784054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.
    Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X
    Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
    Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.
    Trabelsi Grati O; Zemoura L; Nhy C; Daniel C; Melaabi S; Callens C; Gauthier Villars M; Bièche I; Girard N
    Lung Cancer; 2022 Dec; 174():186-187. PubMed ID: 36156246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched-Pair Cohort Study Using a Nationwide Inpatient Database.
    Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
    Clin Lung Cancer; 2024 Sep; 25(6):e243-e251. PubMed ID: 38909011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.